BlueTree Technologies

BlueTree TechnologiesBlueTree Technologies
BlueTree Technologies

BlueTree Technologies

Develops proprietary technology to selectively reduce sugar content in 100% squeezed natural orange juice.

DR 82017Active10Tel Aviv, Israel
Rate

About

BlueTree Technologies offers a patented physical selective technology that dramatically reduces sugar content in natural beverages while preserving great taste and essential nutrients. Their adaptable turnkey platform enables the global production of healthier, great-tasting natural beverages with reduced sugar for manufacturers. They aim to help parents provide children with healthier natural beverages without high sugar levels.
Frequently asked

What does BlueTree Technologies do?

BlueTree Technologies offers a patented physical selective technology that dramatically reduces sugar content in natural beverages while preserving great taste and essential nutrients. Their adaptable turnkey platform enables the global production of healthier, great-tasting natural beverages with reduced sugar for manufacturers. They aim to help parents provide children with healthier natural beverages without high sugar levels.

What is BlueTree Technologies's valuation?

StartupHub estimates BlueTree Technologies's effective valuation at $8.8M (range $5.7M to $13.6M, 14% confidence), based on comparable companies in the sector.

How much funding has BlueTree Technologies raised?

BlueTree Technologies has raised a total of $2M in funding. The most recent round on record is Seed.

Where is BlueTree Technologies headquartered?

BlueTree Technologies is headquartered in Tel Aviv, Israel.

When was BlueTree Technologies founded?

BlueTree Technologies was founded in 2017.

What industry does BlueTree Technologies operate in?

BlueTree Technologies operates in Food, Sugar, FoodTech, AgTech, HealthTech, Beverage Technology.

How many employees does BlueTree Technologies have?

BlueTree Technologies has approximately 10 people on record.

HEADCOUNT
10
DOMAIN RATING
8
Comments

No comments yet. Be the first to share your take.